STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

FENC FENNEC PHARMACEUTICALS INCORPORATED StockScouter® Report

2

StockScouter® Score

FENNEC PHARMACEUTICALS INCORPORATED, a small cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • The multi-period measure of relative price change and consistency is well below average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 40% done.
Progress: 40% done.
Low
High

Core Model Grades

D
C
F
F

Previous Ratings

6
5
4